Organoid-based Blood Glucose Control In Kidney Transplant
Recipients With Type 1 Diabetes
Type-1 diabetes (T1D) both leads to and worsens outcomes for kidney transplants
Diabetes is leading cause of
kidney disease in the US. 1 of 3 on the kidney transplant waiting list has diabetic
end-stage renal disease
Type-1 diabetics see the worst
outcomes post-transplant, with survival dropping to half that of non-diabetics in 15
years
PRO-303 would offer an ideal solution for the ~ 60K T1D patients living post-kidney transplant
Kidney transplant
recipients are
already treated with chronic immunosuppressives
That treatment would also
prevent
rejection of donor islets used with R-VECs
•PRO-303, injected
subcutaneously, would provide long-lasting blood glucose control to preserve donor
kidney function and avoid T1D-related complications
R-VECs + donor islets have demonstrated tight & sustained blood glucose control in a hyperglycemic
mouse model, with validation in a pig model planned.
FDA feedback has been incorporated into the preclinical plan, potentially enabling IND submission within
two years